Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 24 | 2020 | 200 | 6.880 |
Why?
|
Antineoplastic Agents | 15 | 2020 | 611 | 3.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 462 | 2.780 |
Why?
|
Salvage Therapy | 4 | 2019 | 134 | 1.420 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 105 | 1.350 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2020 | 95 | 1.170 |
Why?
|
Cytarabine | 7 | 2020 | 55 | 1.160 |
Why?
|
Apoptosis | 8 | 2019 | 368 | 1.090 |
Why?
|
Fluorodeoxyuridylate | 3 | 2016 | 23 | 1.060 |
Why?
|
Neoplasms | 3 | 2018 | 695 | 1.050 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 44 | 1.050 |
Why?
|
Sulfides | 6 | 2019 | 27 | 1.040 |
Why?
|
Caprylates | 6 | 2019 | 28 | 1.040 |
Why?
|
Enzyme Inhibitors | 3 | 2020 | 176 | 1.020 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2014 | 79 | 0.930 |
Why?
|
Bone Marrow | 3 | 2020 | 71 | 0.890 |
Why?
|
Mitochondria | 4 | 2019 | 188 | 0.840 |
Why?
|
Cell Membrane | 1 | 2020 | 103 | 0.690 |
Why?
|
Aged | 22 | 2020 | 10398 | 0.660 |
Why?
|
Humans | 36 | 2020 | 32297 | 0.650 |
Why?
|
Mice, Inbred C57BL | 7 | 2017 | 773 | 0.640 |
Why?
|
Middle Aged | 21 | 2020 | 11949 | 0.630 |
Why?
|
Body Composition | 1 | 2020 | 384 | 0.620 |
Why?
|
Resuscitation Orders | 1 | 2017 | 12 | 0.610 |
Why?
|
Glycerophosphates | 1 | 2017 | 4 | 0.600 |
Why?
|
Myelodysplastic Syndromes | 2 | 2014 | 24 | 0.590 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 370 | 0.590 |
Why?
|
Deoxycytidine | 1 | 2017 | 68 | 0.580 |
Why?
|
Intensive Care Units | 1 | 2017 | 118 | 0.570 |
Why?
|
Neoplasm Proteins | 2 | 2014 | 149 | 0.570 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2019 | 18 | 0.560 |
Why?
|
Leukemia | 2 | 2014 | 40 | 0.560 |
Why?
|
Nucleosides | 1 | 2016 | 10 | 0.540 |
Why?
|
Female | 23 | 2020 | 20126 | 0.530 |
Why?
|
Survival Rate | 7 | 2020 | 894 | 0.520 |
Why?
|
DNA Topoisomerases, Type I | 2 | 2012 | 9 | 0.520 |
Why?
|
Thymidylate Synthase | 2 | 2012 | 14 | 0.520 |
Why?
|
Cytogenetics | 1 | 2015 | 7 | 0.510 |
Why?
|
Animals | 12 | 2018 | 7694 | 0.510 |
Why?
|
Mice | 9 | 2018 | 2524 | 0.510 |
Why?
|
Fas Ligand Protein | 1 | 2014 | 8 | 0.500 |
Why?
|
Male | 22 | 2020 | 19488 | 0.500 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 21 | 0.500 |
Why?
|
Membrane Microdomains | 1 | 2014 | 24 | 0.500 |
Why?
|
Prognosis | 9 | 2020 | 1523 | 0.490 |
Why?
|
Lipids | 1 | 2016 | 226 | 0.480 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 34 | 0.480 |
Why?
|
Pyrimidines | 1 | 2014 | 65 | 0.480 |
Why?
|
DNA Damage | 4 | 2017 | 100 | 0.460 |
Why?
|
Azacitidine | 1 | 2013 | 28 | 0.460 |
Why?
|
Mitoxantrone | 3 | 2019 | 19 | 0.460 |
Why?
|
Remission Induction | 5 | 2020 | 84 | 0.460 |
Why?
|
Aged, 80 and over | 9 | 2020 | 4050 | 0.440 |
Why?
|
Adult | 13 | 2020 | 9467 | 0.430 |
Why?
|
Oncogene Proteins | 1 | 2012 | 6 | 0.430 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 24 | 0.430 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2012 | 43 | 0.420 |
Why?
|
DNA Methylation | 1 | 2013 | 142 | 0.420 |
Why?
|
Treatment Outcome | 8 | 2020 | 3358 | 0.420 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 72 | 0.410 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 94 | 0.410 |
Why?
|
Disease Models, Animal | 5 | 2014 | 1040 | 0.390 |
Why?
|
Tandem Repeat Sequences | 1 | 2011 | 6 | 0.390 |
Why?
|
Leukemia, Myeloid | 1 | 2011 | 24 | 0.380 |
Why?
|
Membrane Proteins | 1 | 2012 | 260 | 0.380 |
Why?
|
Cell Line, Tumor | 5 | 2017 | 736 | 0.370 |
Why?
|
Aniline Compounds | 2 | 2020 | 27 | 0.360 |
Why?
|
Geriatric Assessment | 4 | 2020 | 395 | 0.360 |
Why?
|
Prospective Studies | 7 | 2020 | 2274 | 0.350 |
Why?
|
Doxorubicin | 3 | 2017 | 79 | 0.340 |
Why?
|
Recurrence | 3 | 2019 | 266 | 0.310 |
Why?
|
Mutation | 2 | 2020 | 503 | 0.300 |
Why?
|
Follow-Up Studies | 4 | 2020 | 2296 | 0.290 |
Why?
|
Survival Analysis | 4 | 2020 | 491 | 0.280 |
Why?
|
Pancreatic Neoplasms | 2 | 2019 | 142 | 0.280 |
Why?
|
Retrospective Studies | 6 | 2018 | 3514 | 0.280 |
Why?
|
Adenocarcinoma | 2 | 2019 | 315 | 0.260 |
Why?
|
Neoplasm Transplantation | 2 | 2017 | 75 | 0.250 |
Why?
|
Neoplasm Staging | 2 | 2018 | 459 | 0.250 |
Why?
|
Age Factors | 4 | 2018 | 1204 | 0.240 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 279 | 0.240 |
Why?
|
Mice, Transgenic | 2 | 2017 | 261 | 0.230 |
Why?
|
Transcriptional Elongation Factors | 1 | 2003 | 1 | 0.230 |
Why?
|
RNA Polymerase II | 1 | 2003 | 2 | 0.220 |
Why?
|
Genes, Regulator | 1 | 2003 | 5 | 0.220 |
Why?
|
Guanosine Triphosphate | 1 | 2003 | 8 | 0.220 |
Why?
|
International Agencies | 2 | 2019 | 9 | 0.220 |
Why?
|
Comorbidity | 5 | 2018 | 572 | 0.210 |
Why?
|
Transcription, Genetic | 1 | 2003 | 143 | 0.210 |
Why?
|
Electron Transport | 2 | 2019 | 16 | 0.200 |
Why?
|
Hyperglycemia | 2 | 2018 | 84 | 0.190 |
Why?
|
RNA, Messenger | 1 | 2003 | 534 | 0.190 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2020 | 7 | 0.190 |
Why?
|
Benzimidazoles | 1 | 2020 | 34 | 0.180 |
Why?
|
Pyrazines | 1 | 2019 | 14 | 0.180 |
Why?
|
Young Adult | 2 | 2018 | 2626 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 40 | 0.170 |
Why?
|
Heme | 1 | 2019 | 61 | 0.160 |
Why?
|
Cell Proliferation | 2 | 2018 | 602 | 0.160 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 10 | 0.160 |
Why?
|
Citric Acid Cycle | 1 | 2018 | 11 | 0.160 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 567 | 0.160 |
Why?
|
Cell Respiration | 1 | 2018 | 22 | 0.160 |
Why?
|
Protein Biosynthesis | 1 | 2018 | 45 | 0.160 |
Why?
|
Retreatment | 1 | 2018 | 42 | 0.150 |
Why?
|
HL-60 Cells | 2 | 2014 | 14 | 0.150 |
Why?
|
Proportional Hazards Models | 3 | 2015 | 759 | 0.150 |
Why?
|
Philadelphia Chromosome | 1 | 2017 | 4 | 0.150 |
Why?
|
Protein Kinase C | 1 | 2017 | 32 | 0.150 |
Why?
|
Tumor Burden | 1 | 2017 | 61 | 0.150 |
Why?
|
Hematologic Diseases | 1 | 2017 | 24 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2017 | 58 | 0.150 |
Why?
|
Oxygen Consumption | 1 | 2018 | 150 | 0.150 |
Why?
|
Patient Transfer | 1 | 2017 | 44 | 0.150 |
Why?
|
Splenomegaly | 1 | 2016 | 7 | 0.140 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 10 | 0.140 |
Why?
|
Cosmic Radiation | 1 | 2016 | 14 | 0.140 |
Why?
|
Cell Line | 1 | 2018 | 462 | 0.140 |
Why?
|
Biopsy | 1 | 2018 | 273 | 0.140 |
Why?
|
Random Allocation | 1 | 2017 | 220 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 17 | 0.140 |
Why?
|
DNA, Neoplasm | 2 | 2013 | 56 | 0.140 |
Why?
|
Radiation Injuries | 1 | 2016 | 72 | 0.140 |
Why?
|
Biological Availability | 1 | 2016 | 22 | 0.140 |
Why?
|
Tumor Cells, Cultured | 2 | 2016 | 171 | 0.140 |
Why?
|
Blood Glucose | 1 | 2018 | 496 | 0.130 |
Why?
|
Asparaginase | 1 | 2015 | 5 | 0.130 |
Why?
|
Depression | 2 | 2016 | 436 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 675 | 0.130 |
Why?
|
Activities of Daily Living | 1 | 2016 | 258 | 0.130 |
Why?
|
Transplantation, Homologous | 1 | 2015 | 151 | 0.130 |
Why?
|
Tumor Stem Cell Assay | 1 | 2014 | 12 | 0.130 |
Why?
|
Ribonucleotide Reductases | 1 | 2014 | 6 | 0.130 |
Why?
|
Cognition | 2 | 2016 | 551 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 65 | 0.120 |
Why?
|
Lung | 1 | 2016 | 262 | 0.120 |
Why?
|
Polypharmacy | 1 | 2014 | 20 | 0.120 |
Why?
|
Oligonucleotides | 1 | 2014 | 30 | 0.120 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 100 | 0.120 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 2 | 2011 | 8 | 0.120 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 171 | 0.120 |
Why?
|
Drug Evaluation | 1 | 2013 | 15 | 0.120 |
Why?
|
Stem Cells | 1 | 2016 | 310 | 0.120 |
Why?
|
Occupational Exposure | 1 | 2016 | 238 | 0.120 |
Why?
|
Databases, Factual | 1 | 2015 | 355 | 0.110 |
Why?
|
Hospitalization | 2 | 2018 | 465 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 190 | 0.110 |
Why?
|
Gene Fusion | 1 | 2012 | 2 | 0.110 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2012 | 6 | 0.110 |
Why?
|
Translocation, Genetic | 1 | 2012 | 21 | 0.110 |
Why?
|
Phenotype | 1 | 2015 | 656 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 8 | 0.110 |
Why?
|
DNA Replication | 1 | 2012 | 34 | 0.110 |
Why?
|
Homeodomain Proteins | 1 | 2012 | 51 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 49 | 0.110 |
Why?
|
Lung Neoplasms | 1 | 2016 | 409 | 0.110 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 316 | 0.110 |
Why?
|
Trans-Activators | 1 | 2012 | 46 | 0.100 |
Why?
|
Histones | 1 | 2012 | 54 | 0.100 |
Why?
|
Inhibitory Concentration 50 | 1 | 2012 | 23 | 0.100 |
Why?
|
Substrate Specificity | 1 | 2012 | 90 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2012 | 119 | 0.100 |
Why?
|
Transcription Factors | 1 | 2012 | 181 | 0.100 |
Why?
|
Benzenesulfonates | 1 | 2011 | 3 | 0.100 |
Why?
|
Gene Duplication | 1 | 2011 | 5 | 0.100 |
Why?
|
Phenylurea Compounds | 1 | 2011 | 10 | 0.100 |
Why?
|
Niacinamide | 1 | 2011 | 8 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 849 | 0.100 |
Why?
|
Signal Transduction | 1 | 2014 | 701 | 0.090 |
Why?
|
RNA Interference | 1 | 2011 | 77 | 0.090 |
Why?
|
Pyridines | 1 | 2011 | 81 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 264 | 0.090 |
Why?
|
Acute Disease | 1 | 2011 | 255 | 0.090 |
Why?
|
Blotting, Western | 1 | 2011 | 305 | 0.090 |
Why?
|
Risk Factors | 2 | 2015 | 3876 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 920 | 0.080 |
Why?
|
Time Factors | 1 | 2015 | 2181 | 0.080 |
Why?
|
Leucovorin | 2 | 2019 | 25 | 0.080 |
Why?
|
Fluorouracil | 2 | 2019 | 82 | 0.080 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 1133 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2015 | 1428 | 0.070 |
Why?
|
Macromolecular Substances | 1 | 2003 | 18 | 0.060 |
Why?
|
Molecular Weight | 1 | 2003 | 43 | 0.060 |
Why?
|
Saccharomyces cerevisiae | 1 | 2003 | 20 | 0.060 |
Why?
|
Binding Sites | 1 | 2003 | 132 | 0.050 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2012 | 17 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 149 | 0.050 |
Why?
|
DNA | 1 | 2003 | 229 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 72 | 0.050 |
Why?
|
Daunorubicin | 1 | 2020 | 27 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2020 | 320 | 0.040 |
Why?
|
Electron Transport Chain Complex Proteins | 1 | 2019 | 8 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2019 | 12 | 0.040 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2019 | 17 | 0.040 |
Why?
|
Administration, Oral | 1 | 2019 | 185 | 0.040 |
Why?
|
Mitochondrial Membranes | 1 | 2019 | 21 | 0.040 |
Why?
|
Transduction, Genetic | 1 | 2019 | 42 | 0.040 |
Why?
|
Sulfonamides | 1 | 2019 | 67 | 0.040 |
Why?
|
Lymphopenia | 1 | 2017 | 12 | 0.040 |
Why?
|
Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
Neutropenia | 1 | 2017 | 30 | 0.040 |
Why?
|
Hypoalbuminemia | 1 | 2017 | 12 | 0.040 |
Why?
|
Sensation Disorders | 1 | 2017 | 20 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2017 | 32 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 60 | 0.040 |
Why?
|
Camptothecin | 1 | 2017 | 53 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 47 | 0.040 |
Why?
|
Body Burden | 1 | 2016 | 7 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2017 | 45 | 0.040 |
Why?
|
Astronauts | 1 | 2016 | 8 | 0.040 |
Why?
|
Anemia | 1 | 2017 | 60 | 0.040 |
Why?
|
Topotecan | 1 | 2016 | 17 | 0.040 |
Why?
|
Radiation Dosage | 1 | 2016 | 81 | 0.030 |
Why?
|
Liver | 1 | 2019 | 486 | 0.030 |
Why?
|
Genome, Human | 1 | 2016 | 133 | 0.030 |
Why?
|
Physical Examination | 1 | 2016 | 94 | 0.030 |
Why?
|
Sepsis | 1 | 2017 | 156 | 0.030 |
Why?
|
Mental Health | 1 | 2016 | 113 | 0.030 |
Why?
|
Patient Discharge | 1 | 2016 | 183 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 410 | 0.030 |
Why?
|
Survivors | 1 | 2016 | 157 | 0.030 |
Why?
|
Mobility Limitation | 1 | 2016 | 221 | 0.030 |
Why?
|
Logistic Models | 1 | 2015 | 788 | 0.030 |
Why?
|
Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2012 | 2 | 0.030 |
Why?
|
Thymine | 1 | 2012 | 6 | 0.030 |
Why?
|
S Phase | 1 | 2012 | 15 | 0.030 |
Why?
|
Alkaloids | 1 | 2012 | 9 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2013 | 65 | 0.030 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2012 | 21 | 0.030 |
Why?
|
Nursing Assessment | 1 | 2011 | 11 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2013 | 696 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2011 | 294 | 0.020 |
Why?
|
Motor Activity | 1 | 2013 | 327 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 877 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2011 | 236 | 0.020 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 8 | 0.020 |
Why?
|
Genes, ras | 1 | 2009 | 25 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2009 | 16 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 262 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2009 | 326 | 0.020 |
Why?
|
Genotype | 1 | 2009 | 742 | 0.020 |
Why?
|
Cohort Studies | 1 | 2011 | 1832 | 0.020 |
Why?
|
North Carolina | 1 | 2011 | 1520 | 0.020 |
Why?
|